^
    Back
    Association details:
    Biomarker:ROS1 rearrangement + PD-L1 overexpression
    Cancer:Lung Adenocarcinoma
    Regimen: (Avastin (bevacizumab) + carboplatin + paclitaxel + Tecentriq (atezolizumab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Oncol Res Ther
    Title:

    Response to ABCP Regimen in a ROS1Rearranged Lung Adenocarcinoma Patient with Brain Metastases and High PD-L1 Expression: A Case Report

    Published date:
    11/29/2022
    Excerpt:
    We report a case of a 42-year-old female with ROS1-rearranged NSCLC and high PD-L1 expression treated with atezolizumab (1200 mg) / bevacizumab (7.5 mg/kg) / carboplatin (AUC 5) / pemetrexed (500 mg/m2) (ABCP) regimen after failure of targeted therapy. After 2 cycles, she achieved partial response (PR) and confirmed PR after 4 cycles of ABCP regimen not only in the primary lung lesion, but also in multiple metastatic lesions of the brain.
    DOI:
    https://doi.org/10.29011/2574710X.10151